^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug: | Torisel (temsirolimus) (mTOR inhibitor) + refametinib (BAY86-9766) (MEK inhibitor, ERK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus
Excerpt:
This inhibitory effect of RDEA119 in selected cell lines OCUT1 (BRAF V600E(+), PIK3CA H1047R(+)) and SW1376 (BRAF V600E(+)) was enhanced by combination with the mTOR inhibitor, temsirolimus.
DOI:
10.1002/ijc.25304
